Nemonapride

Nemonapride (エミレース, Emilace (JP)) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in May 1991.[1] Nemonapride acts as a D2 and D3 receptor antagonist, and is also a potent 5-HT1A receptor agonist.[2] It has affinity for sigma receptors.

Nemonapride
Clinical data
Trade namesEmilace (JP)
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • Rx-only (JP)
Identifiers
IUPAC name
  • N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
Chemical and physical data
FormulaC21H26ClN3O2
Molar mass387.91 g·mol−1
3D model (JSmol)
SMILES
  • CC1C(CCN1CC2=CC=CC=C2)NC(=O)C3=CC(=C(C=C3OC)NC)Cl
InChI
  • InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26)
  • Key:KRVOJOCLBAAKSJ-UHFFFAOYSA-N
  (verify)

See also
  • Benzamide

References
  1. "Pharmaceuticals and Medical Devices Safety Information No. 265" (PDF). Pharmaceuticals and Medical Devices Agency. January 2010. Archived from the original (PDF) on 26 July 2022. Retrieved 26 July 2022.
  2. Kusumi I, Boku S, Takahashi Y (May 2015). "Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis". Psychiatry and Clinical Neurosciences. Wiley. 69 (5): 243–258. doi:10.1111/pcn.12242. PMID 25296946. S2CID 23102204.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.